PMID- 15922965
OWN - NLM
STAT- MEDLINE
DCOM- 20051006
LR  - 20210102
IS  - 1525-0016 (Print)
IS  - 1525-0016 (Linking)
VI  - 11
IP  - 6
DP  - 2005 Jun
TI  - Enhanced immunity by NeuEDhsp70 DNA vaccine Is needed to combat an aggressive 
      spontaneous metastatic breast cancer.
PG  - 941-9
AB  - The rapid growth and ruthless metastasis of tumors demand effective broad immune 
      responses. Dendritic cells (DCs) are critical in developing tumor vaccines. 
      Recent investigations have been focused on modifying tumor antigens to target DCs 
      to induce immune responses efficiently in vivo. In this study, human hsp70 was 
      fused to the extracellular domain of rat Her2/Neu (NeuEDhsp70) for enhancing 
      anti-tumor immunity in aggressive breast tumor models. NeuEDhsp70-conditioned DCs 
      produced significant IL-12p40 and effectively presented NeuED antigens to T cells 
      in vitro. NeuEDhsp70 DNA vaccine induced enhanced Neu-specific antibody and 
      IFN-gamma-producing cellular immune responses in vivo. Although NeuEDhsp70 and 
      NeuED DNA vaccines elicited comparable therapeutic anti-tumor immunity in an 
      aggressive primary breast tumor model, NeuEDhsp70 DNA vaccine significantly 
      increased survival and reduced metastasis in an aggressive spontaneous metastatic 
      breast tumor model. Results from animal experiments with depletion of immune 
      cells or with deficiency of CD40 molecules indicate that T cells and CD40 
      molecules are critical in the anti-tumor immunity induced by NeuEDhsp70 DNA 
      vaccine. These observations suggest that NeuEDhsp70 DNA vaccine is a promising 
      reagent to induce potent anti-tumor immunity to an aggressive spontaneous 
      metastatic breast tumor.
FAU - Kim, Jin H
AU  - Kim JH
AD  - Department of Dermatology and University of Pittsburgh Cancer Institute, 
      University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
FAU - Majumder, Nilanjana
AU  - Majumder N
FAU - Lin, Honghui
AU  - Lin H
FAU - Chen, Janet
AU  - Chen J
FAU - Falo, Louis D Jr
AU  - Falo LD Jr
FAU - You, Zhaoyang
AU  - You Z
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Mol Ther
JT  - Molecular therapy : the journal of the American Society of Gene Therapy
JID - 100890581
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (CD40 Antigens)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Interleukin-12 Subunit p40)
RN  - 0 (NeuEDhsp70 fusion protein, recombinant)
RN  - 0 (Protein Subunits)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (Vaccines, DNA)
RN  - 187348-17-0 (Interleukin-12)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/immunology
MH  - Bone Marrow Neoplasms/*prevention & control/secondary
MH  - CD4-Positive T-Lymphocytes/immunology
MH  - CD40 Antigens/analysis
MH  - Cancer Vaccines/genetics/*immunology/*therapeutic use
MH  - Dendritic Cells/immunology
MH  - Female
MH  - Interleukin-12/analysis
MH  - Interleukin-12 Subunit p40
MH  - Mammary Neoplasms, Animal/*drug therapy/immunology/pathology
MH  - Mice
MH  - Protein Subunits/analysis
MH  - Rats
MH  - Receptor, ErbB-2/immunology
MH  - Recombinant Fusion Proteins/genetics/*immunology
MH  - Vaccines, DNA/immunology/therapeutic use
EDAT- 2005/06/01 09:00
MHDA- 2005/10/07 09:00
CRDT- 2005/06/01 09:00
PHST- 2004/08/06 00:00 [received]
PHST- 2004/12/27 00:00 [revised]
PHST- 2005/01/05 00:00 [accepted]
PHST- 2005/06/01 09:00 [pubmed]
PHST- 2005/10/07 09:00 [medline]
PHST- 2005/06/01 09:00 [entrez]
AID - S1525-0016(05)00005-5 [pii]
AID - 10.1016/j.ymthe.2005.01.003 [doi]
PST - ppublish
SO  - Mol Ther. 2005 Jun;11(6):941-9. doi: 10.1016/j.ymthe.2005.01.003.